User:Mr. Ibrahem/Tremelimumab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CTLA-4 |
| Clinical data | |
| Trade names | Imjudo |
| Other names | tremelimumab-actl; ticilimumab; CP-675; CP-675,206[1] |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Immune checkpoint blocker[2] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6500H9974N1726O2026S52 |
| Molar mass | 146382.47 g·mol−1 |
  (what is this?) (verify) | |
Tremelimumab, sold under the brand name Imjudo, is a medication used to treat hepatocellular cancer that cannot be removed by surgery alone and certain types of non-small cell lung cancer (NSCLC) which has spread to other parts of the body.[3] It is generally used with durvalumab.[3] It is given by gradual injection into a vein.[3]
Common side effects include rash, diarrhea, tiredness, itchiness, and muscle pain.[3] Other side effects may include immune system problems such as pneumonitis, colitis, and hepatitis; and infusion reactions.[3] Use in pregnancy may harm the baby.[3] It is a monoclonal antibody and immune checkpoint blocker that blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).[3][2]
Tremelimumab was approved for medical use in the United States in 2022.[3] As of 2022 the manufacturer has applied for approval in Europe.[4] In the United States 75 mg costs about 10,300 USD as of 2022.[5]
References[edit]
- ^ "Tremelimumab". National Cancer Institute. Archived from the original on 10 August 2019. Retrieved 27 October 2022.
This article incorporates text from this source, which is in the public domain.
- ^ a b Wang, BC; Li, PC; Fan, JQ; Lin, GH; Liu, Q (10 July 2020). "Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis". Medicine. 99 (28): e21273. doi:10.1097/MD.0000000000021273. PMID 32664183.
- ^ a b c d e f g h i j k "DailyMed - IMJUDO- tremelimumab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 18 November 2022. Retrieved 16 December 2022.
- ^ "Tremelimumab". SPS - Specialist Pharmacy Service. 28 November 2020. Archived from the original on 15 December 2021. Retrieved 16 December 2022.
- ^ "Imjudo Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 16 December 2022.
